A new method of modeling drug-target interactions fixes a detrimental bias of past techniques
"Drug discovery is a very long process. At each stage, you may find your drug is not good enough and you need to seek another candidate," explains A*STAR's Xiao-Li Li. His team won 'best paper' at the 2016 International Conference ...